What is 5-Amino-1MQ, and why the interest?

5-Amino-1MQ, short for 5-amino-1-methylquinolinium, is a small molecule that inhibits an enzyme called nicotinamide N-methyltransferase, or NNMT. It is not a peptide. Researchers became interested in it because changing NNMT activity can affect how cells handle nutrients and store fat.

NNMT uses a methyl donor called SAM to convert nicotinamide into 1-methylnicotinamide. Nicotinamide also supplies the pathway cells use to recycle NAD+, which supports many metabolic reactions. In cultured mouse fat cells, 5-Amino-1MQ increased NAD+ and SAM and reduced lipid accumulation. Those findings explain the proposed mechanism; they do not show that taking the compound raises NAD+ or improves metabolism in a person. Cell and mouse study

A frequently cited 2014 experiment reduced NNMT production in mouse fat and liver using antisense molecules. The mice resisted diet-induced obesity and used more energy. That helped establish NNMT as a research target, but it was a different intervention from 5-Amino-1MQ. Results from other NNMT inhibitors also need to be checked against the exact molecule used. Genetic knockdown study

What did the weight and metabolic studies find?

The early weight-loss result: In a study published in 2018, 18 obese male mice were divided into two groups. One received 5-Amino-1MQ injections under the skin three times daily for 11 days; the other received saline. Treated mice lost about 5.1% of their starting weight, while controls gained about 1.4%. A measured abdominal fat depot was smaller, and cholesterol was lower. Food intake did not differ significantly. This was a short experiment in nine mice per group, with injections rather than capsules. 2018 original study

Combining treatment with a diet change: A 2021 experiment followed small groups of male mice for about seven weeks. Obese mice switched to a lower-fat diet and given daily 5-Amino-1MQ injections lost more weight and fat than mice switched to that diet alone. Average fat mass fell by about 29.3% with the combination, versus 2.9% with the diet change alone. Liver fat also improved. The relevant groups each contained eight mice; the study does not tell us whether people would obtain the same result. Diet-combination study

Less further weight gain: A 2024 study assigned 24 obese male mice to saline or one of two daily injected doses for about four weeks. The higher-dose group gained 0.9 grams, compared with 5.4 grams in controls. Glucose tolerance, circulating insulin and several liver measures improved. The lower dose did not produce the same weight result, and ordinary fed-state glucose and lean mass did not significantly change. This experiment showed less weight gain, not weight loss. 2024 metabolic study

These results support further investigation. Unchanged measured food intake is useful information, but it does not by itself prove an increase in energy expenditure or establish what someone would feel in terms of hunger.

What about muscle and healthy aging?

A separate 2024 study used 35 aged female mice, divided between sedentary and exercise groups with or without daily 5-Amino-1MQ injections. Over the eight-week experiment, treatment improved grip strength and helped exercising mice maintain running performance. The findings were mixed across measures: peak force in the tested lower-leg muscles did not significantly improve, and treatment did not significantly increase their body-weight-adjusted muscle masses. This is interesting muscle research, but it does not establish treatment for human sarcopenia or longer life. Aged-mouse study

What do we know about experiences in people?

The literature and registry searches for this review did not identify a published trial in which people received 5-Amino-1MQ. Searches of ClinicalTrials.gov under its compound names also found no registered trial. This is a dated search finding, not a claim that every unpublished or unregistered study worldwide has been ruled out. Registry search

There is therefore no verified patient-study result here for how much weight someone might lose, whether energy would improve, or how often side effects occur. Personal reports cannot separate the compound from changes in diet, exercise, other treatments or product contents.

Why does the route of administration matter?

The weight studies above used injections. A separate 2021 rat study estimated oral bioavailability, the proportion of an oral dose reaching the circulation, at 38.4%. The 2024 mouse study estimated only 3.5%. These were different species and experimental conditions. Neither establishes human absorption or validates a capsule dose. Rat pharmacokinetics · Mouse pharmacokinetics

A study of an injected research compound also cannot establish the identity, purity or performance of a separately supplied oral product. A certificate of analysis can help document what was tested in a batch; it cannot establish clinical benefit.

What remains uncertain about safety?

The short mouse studies reported tolerability or reassuring findings in the measures assessed. That is useful early information, but it does not establish long-term human safety, interactions, or use during pregnancy. The 2024 metabolic study also found activity against a second enzyme, MAO-A, in laboratory testing. The authors noted that this could contribute to some effects. The consequences for people are unknown. Mouse tolerability findings · Off-target testing

Research funding is not absent: the 2024 papers report NIH and U.S. Department of Defense support. Several authors disclosed founding or employment relationships with Ridgeline Therapeutics. That context belongs alongside the results, without assuming it explains why human evidence is missing. Metabolic-study disclosures · Muscle-study disclosures

Questions worth taking to a clinician

What is supported

  • Changes in fat mass and metabolic measures in specific mouse experiments.
  • A biological reason to investigate NNMT inhibition.
  • Some improved muscle outcomes in aged mice.

What is unresolved

  • Human benefit, absorption and an appropriate dose.
  • Long-term safety and interactions with other medicines.
  • Whether benefits persist after treatment stops.

What to ask

  • Which human study supports the proposed use and route?
  • How does it compare with established options for my goal?
  • What authorization and product testing apply where treatment would occur?

Where the evidence stands

Mechanism

Cell experiments and genetic mouse studies explain the interest in NNMT.

Compound studies

Injected 5-Amino-1MQ has positive and unchanged outcomes in small mouse experiments.

Human treatment

No published administration trial was identified in this review's searches.

Access

A specific FDA warning addresses U.S. 503B compounding. Availability does not establish approval.

Questions people ask

Is 5-Amino-1MQ a peptide or an NAD+ precursor?

It is a small molecule called 5-amino-1-methylquinolinium. It inhibits NNMT, an enzyme involved in nicotinamide and methyl-group metabolism. It does not supply an NAD+ precursor. Higher NAD+ levels in cultured fat cells do not establish an NAD+ increase or a health benefit in people. Mechanism study

Does it cause fat loss without reducing appetite?

An 11-day mouse study found weight loss without a significant difference in measured food intake. A later study found less weight gain, also without a significant food-intake difference. Neither result establishes an appetite effect or a fat-loss benefit in people. Early study · Later study

Have human trials established a safe dose?

The literature and registry searches for this review did not identify a published trial in which people received 5-Amino-1MQ, or a registered trial under the searched compound names. A safe human dose, long-term effects and interactions therefore remain unestablished in the sources reviewed. Animal doses should not be treated as a human protocol. Registry search

What has the FDA said about compounding it?

In its January 20, 2026 warning letter to GenoGenix, FDA said the facility’s 5-Amino-1MQ products did not qualify for section 503B exemptions because the substance was not on the 503B bulks list and the products did not meet the drug-shortage condition. This is a specific U.S. compounding finding. It does not establish eligibility under section 503A or authorization in another country. FDA warning letter

What to take away

  • The interest in 5-Amino-1MQ comes from real cell and animal findings.
  • Results depend on the dose, route, model and measured outcome. Weight loss and reduced weight gain are different findings.
  • The sources reviewed do not establish a human treatment benefit or a safe human protocol.

The evidence

Original research and official sources are listed below. Animal results, a registry search and regulatory findings answer different questions.

GENETIC MOUSE STUDYNicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature (2014). PubMed 24717514
CELLS AND MICESelective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology (2018). PubMed 29155147
MOUSE STUDYCombined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports (2021). PubMed 33707534
MOUSE STUDYNicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism (2024). PubMed 39161060
RAT PHARMACOKINETICSDevelopment & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis (2021). PubMed 34304009
MOUSE STUDYNicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports (2024). PubMed 38969654
REGISTRY SEARCHClinicalTrials.gov search for 5-amino-1MQ. ClinicalTrials.gov (checked November 9, 2026). ClinicalTrials.gov
U.S. REGULATORY SOURCEGenoGenix LLC warning letter, January 20, 2026. U.S. Food and Drug Administration (2026). FDA warning letter

Sources checked November 9, 2026. The registry search is a snapshot and does not exclude unpublished or unregistered work. The 2021 rat pharmacokinetic report was available as an original abstract; the principal mouse reports were read in full.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Animal and laboratory findings do not establish benefits or safety in people. Any treatment decision should be made with a qualified physician. Individual results vary.